ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,227.40
0.58%
Dow Jones
39,164.06
0.09%
Gold vs US Dollar
2,334.935
0.31%
Brent Oil
85.735
0.37%
Bitcoin
61,476.62
-0.21%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC
  6. Daiichi Sankyo Company Ltd (PK) (DSNKY)

  7. Daiichi Sankyo Company Ltd (PK) (DSNKY) News

Daiichi Sankyo (PK) (DSNKY)

Daiichi Sankyo Company Ltd (PK)
Date:
Sort by:
 Showing the most relevant articles for your search:USOTC:DSNKY
DateTimeSourceHeadlineSymbolCompany
23/10/202307:49Dow Jones NewsAstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer TreatmentUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
20/10/202301:30Dow Jones NewsMerck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 BillionUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
22/09/202307:53Dow Jones NewsAstraZeneca Says Trial Results For Breast Cancer Drug Were Highly PositiveUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
15/09/202315:51Dow Jones NewsAstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EUUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
11/09/202307:55Dow Jones NewsAstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control RatesUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
03/07/202307:50Dow Jones NewsAstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer PatientsUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
05/06/202313:53Dow Jones NewsAstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in TrialUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
14/11/202207:52Dow Jones NewsAstraZeneca Says Enhertu Recommended for EU Approval for Gastric CancerUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
12/08/202207:53Dow Jones NewsAstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer TreatmentUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
09/08/202211:49Dow Jones NewsAstraZeneca Reports Promising Data From Lung Cancer TrialUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
27/06/202207:55Dow Jones NewsAstraZeneca Enhertu Breast Cancer Drug Is Recommended for EU ApprovalUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
05/05/202208:03Dow Jones NewsAstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer TreatmentUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
19/04/202207:55Dow Jones NewsAstraZeneca, Daiichi Sankyo Say FDA Has Accepted Enhertu for Priority ReviewUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
21/02/202209:38Dow Jones NewsAstraZeneca, Daiichi Sankyo Report Positive Trial Results for Enhertu Breast-Cancer Treatment -- UpdateUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/01/202207:54Dow Jones NewsAstraZeneca's Enhertu Granted Priority Review by US RegulatorUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/09/202118:05Dow Jones NewsAstraZeneca Sees Positive Results for Enhertu TrialUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
30/03/201907:02Dow Jones NewsCancer Drug Deal Carries High Price -- WSJUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
28/07/201613:10Dow Jones NewsChina's Fosun Close to Deal for India's Gland PharmaUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
20/04/201523:00Dow Jones NewsDaiichi Sankyo to Sell Sun Pharma StakeUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
23/03/201521:44The Motley FoolThis Market Could Grow 6250% in 10 YearsUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
23/03/201514:14The Motley FoolThis Market Could Grow 6250% in 10 YearsUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
02/12/201420:38Dow Jones NewsAbilify Maker Otsuka to Buy Avanir for $3.5 BillionUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
24/01/201401:12Dow Jones NewsFDA Bars Ingredients From Ranbaxy's India PlantUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/09/201311:43Dow Jones NewsASIA MARKETS: China Leads Asia Stocks LowerUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/09/201307:03Dow Jones NewsASIA MARKETS: Asia Stocks Mostly Lower Ahead Of Fed MeetingUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/09/201305:08Dow Jones NewsASIA MARKETS: Asia Stocks Mostly Lower Ahead Of Fed MeetingUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/09/201303:06Dow Jones NewsASIA MARKETS: Asia Stocks Mostly Lower Ahead Of Fed MeetingUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
02/09/201309:35Dow Jones NewsASIA MARKETS: Hong Kong Stocks Jump To Lead Broad Asia GainsUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
02/09/201304:07Dow Jones NewsASIA MARKETS: Hong Kong Stocks Jump To Lead Broad Asia GainsUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
02/09/201302:28Dow Jones NewsASIA MARKETS: Asia Stocks Rise After Official China Factory DataUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
 Showing the most relevant articles for your search:USOTC:DSNKY

Your Recent History

NASDAQ
AAZUYXX
Torontodominion Bank Iss...
AQSE
GBSP.GB
WisdomTree Hedged Commod...
TG
IWIA
Sharc International Syst...
BIT
P1UJF9
NLBNPIT1UJF9 20991231 85...
LSE
YB36
Citi Fun 25
NASDAQ
VTVT
vTv Therapeutics
NASDAQ
MMNKX
Mass Mutual Small Cap Va...
BOV
MELK3
Melnick Desenvolvimento ... ON
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved